Daniel W. Pierce
14Patents
5h-index
32Co-inventors
66Inventor score
Filing activity: Sep 3, 1998 → Sep 27, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10357489B2 | Antiproliferative compounds and methods of use thereof | Human Necessities | 12 | Active |
| US10527604B1 | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel | Physics | 9 | Active |
| US10705070B1 | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug | Physics | 7 | Active |
| US7416856B2 | High sensitivity assay for detection of nucleoside diphosphate production | Physics | 7 | Active |
| US10900951B1 | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel | Physics | 6 | Active |
| US11320416B1 | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug | Physics | 4 | Active |
| US7824880B2 | High sensitivity assay for detection of nucleoside diphosphate production | Physics | 4 | Active |
| US11185543B2 | Antiproliferative compounds and methods of use thereof | Human Necessities | 4 | Active |
| US12061183B2 | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug | Physics | 2 | Active |
| US7252950B1 | Assays for detecting modulators of cytoskeletal function | Physics | 1 | Expired |
| US12053466B2 | Antiproliferative compounds and bispecific antibody against BCMA and CD3 for combined use | Chemistry; Metallurgy | 0 | Active |
| US11439637B2 | Antiproliferative compounds and bispecific antibody against BCMA and CD3 for combined use | Chemistry; Metallurgy | 0 | Active |
| US12029738B2 | Antiproliferative compounds and methods of use thereof | Human Necessities | 0 | Active |
| US12090147B2 | Combination therapy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.